PRL3-zumab is a first-in-class humanized antibody drug that specifically targets PRL3-overexpressing tumors without damaging surrounding healthy tissues, targeting PRL3 externalized on the tumor cell surface.14 This evidence concerns the gene PTP4A3 and neoplasm.